Kardigan, a clinical-stage biopharma company, has filed for an IPO to raise funds for advancing its cardiovascular disease treatments, led by the drug Danicamtiv currently in Phase 2b/3 trials. The company uses its Prolario AI platform to enhance clinical trial design and patient recruitment, aiming to improve trial outcomes and efficiency. With $287 million in cash and strong venture capital support, Kardigan is well-positioned to progress its pipeline. The IPO is expected to attract institutional investors interested in life sciences due to promising trial results and a strategic approach to licensing and market targeting.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Garmin introduced the G2000 PRIME, a new integrated flight deck designed for high-performance Class I/II piston and electric aircraft. It features large, edge-to-edge touchscreen displays with advanced multi-touch capabilities, faster processors, and...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
The global Reactive Hot Melt Adhesives market is projected to grow from USD 2.02 billion in 2025 to USD 4.29 billion by 2035, at a CAGR of 7.72%. Growth is fueled by regulations limiting solvent adhesives, increased use of polyurethane adhesives in a...
Montero Mining completed drillhole MON-ELV-02 to 625.25 meters at its Elvira Gold Project in Chile, successfully testing its top exploration target. The hole confirmed predicted volcanic and porphyry sequences with extensive pyrite and high-sulphidat...
